Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: Described herein are methods for treatment of oral mucositis comprising administering to a patient in need thereof a composition comprising extracts from the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica; in patients treated with a once-weekly regimen of 30-40 mg/m2 of cisplatin.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: At least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition.

Abstract: Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: Described herein are novel compositions comprising a cannabis component selected from the group consisting of: a cannabinoid, a flavonoid and a terpenoid; and a protein, selected from the group consisting of whey and a plant protein. According to an embodiment, the cannabis component is non-covalently bound to the whey or to the plant protein. The plant protein may be selected from the group consisting of: soy protein, pea protein, rice protein, hemp protein, and hops protein or other plant derived protein.

Abstract: Described herein are hydrogel compositions comprising extracts of Sambucus nigra, Centella asiatica and Echinacea purpurea. The compositions were found to have improved wound-healing effects. Also described herein are methods for treatment of a wound comprising administering, topically to a patient in need thereof, a therapeutically effective amount of a hydrogel composition comprising extracts of Sambucus nigra, Centella asiatica and Echinacea purpurea.

Abstract: Embodiments of the disclosure relate to a plant matter burning or vaporization apparatus comprising a plant matter receptacle for containing plant matter, and a burning/vaporization region for burning or vaporization of plant matter to produce a plant compound vapor, and a plant matter conduit operable to continuously convey plant matter to the burning/vaporization region. Embodiments of the disclosure also relate to a solvent combination apparatus comprising or operatively connected to a vapor conduit located at or at a distance from the burning/vaporization region, from which the plant compound vapor is removed from the environment of the plant matter and conveyed to a solvent in which the plant compound vapor is dissolved. The dissolution of the plant compound vapor in the solvent may be assisted by passing the solvent and smoke/vapor through a nozzle creating a region of high pressure.

Abstract: A method for producing a fatty acid-cannabinoid-plasma protein (FCP) composition, the method comprising: contacting a plasma protein or a peptide portion thereof with a supplemental fatty acid composition comprising at least one fatty acid; and contacting the plasma protein or portion thereof with a cannabinoid composition comprising at least one cannabinoid, such that a combined composition is prepared, which comprises a FCP complex in which the at least one fatty acid and the at least one cannabinoid is bound to the plasma protein or portion thereof.

Abstract: At least one protein-bound cannabinoid bound to a plasma protein for use as a medicament for treatment of a condition, wherein a total cannabinoid dose of the at least one protein-bound cannabinoid, administered over a time period comprising multiple administrations, is lower relative to a total cannabinoid dose of the at least one cannabinoid when administered in unbound form for achieving a same degree of therapeutic effect for treating the condition.

Abstract: Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Abstract: Embodiments of the invention relate to a method for the treatment of mIAS or prevention of symptoms associated with mIAS in a patient in need thereof comprising administering to a patient in need thereof an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica. Optionally the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2. Further embodiments relate to use of extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica for the manufacture of a medicament for the treatment of mIAS or prevention of symptoms associated with mIAS in a patient in need thereof.

Abstract: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.

Abstract: Embodiments of the invention relate to a method for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof comprising administering to a patient in need thereof an amount of a composition comprising extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica. Optionally the ratio of Sambucus nigra, Echinacea purpurea and Centella asiatica is about 7:1:2. Further embodiments relate to use of extracts of the plant species Sambucus nigra, Echinacea purpurea, and Centella asiatica for the manufacture of a medicament for the treatment of mlAS or prevention of symptoms associated with mlAS in a patient in need thereof.

Abstract: Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.